Literature DB >> 26584796

Serial evaluation of retinal vascular changes in infants treated with intravitreal bevacizumab for aggressive posterior retinopathy of prematurity in zone I.

T R Padhi1, T Das2, S Rath1, L Pradhan3, S Sutar1, K G Panda1, R Modi1, S Jalali2.   

Abstract

PURPOSE: To evaluate the serial changes in retinal vasculature in infants treated with intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity (APROP) in zone I.
METHODS: Retrospective analysis of serial changes in retinal vasculature after IVB in the seven eyes of four babies with APROP in zone I.
RESULTS: The initial regression, following IVB, was dramatic with reduction in vessel caliber and marked thinning and invisibility of the bridging shunts. Resurgent vascular development was very slow radially though there was continued abnormal vascular growth circumferentially. Common findings in all eyes were tangled vasculature and fine saw-toothed shunts. The variable findings were (1) new closely packed multilayered bridging shunts, long arching mature looking vessels, and finally a ridge at the periphery (n=3 eyes) at 52 weeks of postmenstrual age (PMA); (2) status quo at the stage of saw-toothed shunt and ridge in both eyes for a long time (n=2 eyes); and (3) multiple retinal hemorrhages within the vascularized retina and thick preretinal hemorrhage overlying the saw-toothed shunts and ridge that persisted for another 3 weeks and regressed 2 weeks after laser (n=1). The eyes that received bevacizumab alone (3) did not show any abnormal vascularization at 56 weeks of PMA or beyond.
CONCLUSIONS: The retinal vascularization following IVB was different than normal in terms of its time, speed, and morphology; few of these changes are first to be reported in the literature (Medline search) and warrants further studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26584796      PMCID: PMC4791697          DOI: 10.1038/eye.2015.240

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  36 in total

1.  Final visual acuity results in the early treatment for retinopathy of prematurity study.

Authors:  William V Good; Robert J Hardy; Velma Dobson; Earl A Palmer; Dale L Phelps; Betty Tung; Maryann Redford
Journal:  Arch Ophthalmol       Date:  2010-04-12

Review 2.  The International Classification of Retinopathy of Prematurity revisited.

Authors: 
Journal:  Arch Ophthalmol       Date:  2005-07

3.  Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.

Authors:  Y S Lin; C Nguyen; J L Mendoza; E Escandon; D Fei; Y G Meng; N B Modi
Journal:  J Pharmacol Exp Ther       Date:  1999-01       Impact factor: 4.030

4.  Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.

Authors:  Wei-Chi Wu; Po-Ting Yeh; San-Ni Chen; Chung-May Yang; Chi-Chun Lai; Hsi-Kung Kuo
Journal:  Ophthalmology       Date:  2010-07-29       Impact factor: 12.079

5.  Intravitreal bevacizumab monotherapy for retinopathy of prematurity.

Authors:  Alparslan Şahin; Muhammed Şahin; Abdullah Kürşat Cingü; Yasin Çınar; Fatih Mehmet Türkcü; Harun Yüksel; Savaş Kaya; Şeyhmus Arı; İhsan Caça
Journal:  Pediatr Int       Date:  2013-07-30       Impact factor: 1.524

6.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-12

7.  Diversity of retinal vascular anomalies in patients with familial exudative vitreoretinopathy.

Authors:  Amir H Kashani; Kevin T Brown; Emmanuel Chang; Kimberly A Drenser; Antonio Capone; Michael T Trese
Journal:  Ophthalmology       Date:  2014-07-05       Impact factor: 12.079

8.  Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.

Authors:  Domenico Lepore; Graham E Quinn; Fernando Molle; Antonio Baldascino; Lorenzo Orazi; Maria Sammartino; Velia Purcaro; Carmen Giannantonio; Patrizia Papacci; Costantino Romagnoli
Journal:  Ophthalmology       Date:  2014-07-04       Impact factor: 12.079

9.  Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.

Authors:  Sjakon G Tahija; Rini Hersetyati; Geoffrey C Lam; Shunji Kusaka; Paul G McMenamin
Journal:  Br J Ophthalmol       Date:  2014-01-08       Impact factor: 4.638

10.  Long term refractive and structural outcome following laser treatment for zone 1 aggressive posterior retinopathy of prematurity.

Authors:  Parag K Shah; Minu Ramakrishnan; Bani Sadat; Sandeep Bachu; V Narendran; N Kalpana
Journal:  Oman J Ophthalmol       Date:  2014-09
View more
  6 in total

1.  Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.

Authors:  Tapas Ranjan Padhi; Taraprasad Das; Prabhjot Kaur; Samir Sutar; Ashish Khalsa; Rohit Modi; Hasnat Ali; Lingaraj Pradhan; Subhadra Jalali
Journal:  Int Ophthalmol       Date:  2020-01-10       Impact factor: 2.031

2.  Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography.

Authors:  Aslı Vural; İrfan Perente; İsmail Umut Onur; Erdem Eriş; Zeynep Seymen; Gülsüm Oya Hergünsel; Özgül Salihoğlu; Fadime Ulviye Yiğit
Journal:  Int Ophthalmol       Date:  2018-11-26       Impact factor: 2.031

Review 3.  Aggressive posterior retinopathy of prematurity: a review on current understanding.

Authors:  Devesh Kumawat; Anusha Sachan; Pooja Shah; Rohan Chawla; Parijat Chandra
Journal:  Eye (Lond)       Date:  2021-01-29       Impact factor: 3.775

4.  Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse.

Authors:  Anthony Mukwaya; Pierfrancesco Mirabelli; Anton Lennikov; Muthukumar Thangavelu; Maria Ntzouni; Lasse Jensen; Beatrice Peebo; Neil Lagali
Journal:  Angiogenesis       Date:  2019-09-04       Impact factor: 9.596

Review 5.  Role of cytokines and treatment algorithms in retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Curr Opin Ophthalmol       Date:  2017-05       Impact factor: 3.761

6.  Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.

Authors:  Swapnil M Parchand; Deepanshu Agrawal; Anil Gangwe; Tripti Saraogi; Deepshikha Agrawal
Journal:  Indian J Ophthalmol       Date:  2021-08       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.